Current and historical daily PE Ratio for DBVT (
DBV Technologies
) from 2014 to May 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. DBV Technologies stock (DBVT) PE ratio as of May 22 2024 is 0.
More Details
DBV Technologies SA (DBVT) PE Ratio (TTM) Chart
DBV Technologies SA (DBVT) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1278
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| DBV Technologies PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-22 | At Loss | 2024-03-20 | At Loss |
| 2024-05-21 | At Loss | 2024-03-19 | At Loss |
| 2024-05-20 | At Loss | 2024-03-18 | At Loss |
| 2024-05-17 | At Loss | 2024-03-15 | At Loss |
| 2024-05-16 | At Loss | 2024-03-14 | At Loss |
| 2024-05-15 | At Loss | 2024-03-13 | At Loss |
| 2024-05-14 | At Loss | 2024-03-12 | At Loss |
| 2024-05-13 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
DBV Technologies SA (DBVT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
DBV Technologies SA
NAICS : 325412
SIC : 2834
ISIN : US23306J1016
Share Class Description:
DBVT: ADRCompare
Compare
Traded in other countries / regions
DBVT.USADBV.France0QAJ.UKDBVA.Germany IPO Date
2014-10-22Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers